Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer

Lixi Li , Di Zhang , Tingyu Wen, Yun Wu, Dan Lv, Jingtong Zhai, Fei Ma
{"title":"Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer","authors":"Lixi Li ,&nbsp;Di Zhang ,&nbsp;Tingyu Wen,&nbsp;Yun Wu,&nbsp;Dan Lv,&nbsp;Jingtong Zhai,&nbsp;Fei Ma","doi":"10.1016/j.jncc.2022.09.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Because of the rarity of occult breast cancer (OBC) and limited experience in OBC treatment, the optimal treatment strategy is unknown. This study aimed to compare the efficacy of axillary lymph node dissection (ALND) plus radiotherapy with that of mastectomy plus ALND in patients with OBC.</p></div><div><h3>Methods</h3><p>Relevant clinical data between January 2004 and December 2015 were retrospectively collected from the Surveillance, Epidemiology, and End Results database. The clinical characteristics and prognoses of patients who underwent ALND plus radiotherapy or mastectomy plus ALND were compared before and after propensity score matching.</p></div><div><h3>Results</h3><p>Overall, 569 eligible patients with OBC were included in this study. Of these, 247 patients underwent ALND plus radiotherapy and 322 underwent mastectomy plus ALND. The 5-year overall survival (OS) rates in the ALND plus radiotherapy group and the mastectomy plus ALND group were 89.2% and 80.6%, respectively; and the corresponding 5-year breast cancer-specific survival (BCSS) rates were 95.2% and 93.0%, respectively. After propensity score matching, the OS in the ALND plus radiotherapy group was significantly better than that in the mastectomy plus ALND group. In addition, further subgroup analyses revealed that ALND plus radiotherapy prolonged OS in the pN3 subgroup. Among patients receiving adjuvant chemotherapy, those who underwent ALND plus radiotherapy had better BCSS and OS than those who underwent mastectomy plus ALND.</p></div><div><h3>Conclusions</h3><p>ALND plus radiotherapy could improve the OS of patients with OBC, especially those with pN3 disease and those receiving chemotherapy. ALND combined with radiotherapy is the optimal treatment strategy for patients with imaging-negative OBC.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 198-204"},"PeriodicalIF":7.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000631/pdfft?md5=d20717360977b528252cdfab4cced432&pid=1-s2.0-S2667005422000631-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005422000631","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Because of the rarity of occult breast cancer (OBC) and limited experience in OBC treatment, the optimal treatment strategy is unknown. This study aimed to compare the efficacy of axillary lymph node dissection (ALND) plus radiotherapy with that of mastectomy plus ALND in patients with OBC.

Methods

Relevant clinical data between January 2004 and December 2015 were retrospectively collected from the Surveillance, Epidemiology, and End Results database. The clinical characteristics and prognoses of patients who underwent ALND plus radiotherapy or mastectomy plus ALND were compared before and after propensity score matching.

Results

Overall, 569 eligible patients with OBC were included in this study. Of these, 247 patients underwent ALND plus radiotherapy and 322 underwent mastectomy plus ALND. The 5-year overall survival (OS) rates in the ALND plus radiotherapy group and the mastectomy plus ALND group were 89.2% and 80.6%, respectively; and the corresponding 5-year breast cancer-specific survival (BCSS) rates were 95.2% and 93.0%, respectively. After propensity score matching, the OS in the ALND plus radiotherapy group was significantly better than that in the mastectomy plus ALND group. In addition, further subgroup analyses revealed that ALND plus radiotherapy prolonged OS in the pN3 subgroup. Among patients receiving adjuvant chemotherapy, those who underwent ALND plus radiotherapy had better BCSS and OS than those who underwent mastectomy plus ALND.

Conclusions

ALND plus radiotherapy could improve the OS of patients with OBC, especially those with pN3 disease and those receiving chemotherapy. ALND combined with radiotherapy is the optimal treatment strategy for patients with imaging-negative OBC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
腋窝淋巴结清扫加放疗可能是治疗隐匿性乳腺癌的最佳策略
由于隐匿性乳腺癌(OBC)的罕见性和治疗经验有限,最佳治疗策略尚不清楚。本研究旨在比较腋窝淋巴结清扫(ALND)加放疗与乳腺切除术加ALND治疗乳腺癌的疗效。方法回顾性收集2004年1月至2015年12月监测、流行病学和最终结果数据库中的相关临床资料。比较倾向评分匹配前后行ALND +放疗或乳房切除术+ ALND患者的临床特征和预后。结果本研究共纳入569例符合条件的OBC患者。其中,247名患者接受了ALND +放疗,322名患者接受了乳房切除术+ ALND。ALND +放疗组和乳腺切除术+ ALND组的5年总生存率分别为89.2%和80.6%;相应的5年乳腺癌特异性生存率(BCSS)分别为95.2%和93.0%。倾向评分匹配后,ALND +放疗组的OS明显优于乳腺切除术+ ALND组。此外,进一步的亚组分析显示,ALND加放疗延长了pN3亚组的OS。在接受辅助化疗的患者中,接受ALND +放疗的患者BCSS和OS优于接受乳房切除术+ ALND的患者。结论salnd加放疗可改善肿瘤细胞癌患者的总生存率,尤其是pN3病变及化疗患者。ALND联合放疗是影像阴性肿瘤患者的最佳治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
70 days
期刊最新文献
Editorial Board Cancer survival statistics in China 2019–2021: a multicenter, population-based study Associations between blood glucose and early- and late-onset colorectal cancer: evidence from two prospective cohorts and Mendelian randomization analyses Primary liver cancer organoids and their application to research and therapy DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1